DA-R-EPOCH regimen: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AV}} | {{CMG}}; {{AE}} {{AV}} | ||
{{SK}}DA-EPOCH-R; Dose-adjusted Etoposide/Vincristine/Doxorubicin/Cyclophosphamide/Prednisone Regimen; EPOCH-R regimen; EPOCH-R; EPOCH-R regimen; Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin-Rituximab Regimen | {{SK}}DA-EPOCH-R; Dose-adjusted Etoposide/Vincristine/Doxorubicin/Cyclophosphamide/Prednisone/Rituximab Regimen; EPOCH-R regimen; EPOCH-R; EPOCH-R regimen; Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin-Rituximab Regimen | ||
==Overview== | ==Overview== |
Latest revision as of 18:36, 31 March 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:DA-EPOCH-R; Dose-adjusted Etoposide/Vincristine/Doxorubicin/Cyclophosphamide/Prednisone/Rituximab Regimen; EPOCH-R regimen; EPOCH-R; EPOCH-R regimen; Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin-Rituximab Regimen
Overview
DA-R-EPOCH regimen refers to a chemotherapy regimen consisting of Dose-adjusted etoposide, prednisone, vincristine (Oncovin) ,Cyclophosphamide and doxorubicin (hydroxydaunorubicin hycrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas[1] and HIV-associated B-cell non-Hodgkin lymphoma[2]
Regimen
DADose-adjusted
RRituximab
EEtoposide
PPrednisone
Ovincristine (Oncovin)
CCyclophosphamide
Hdoxorubicin (Hydroxydaunorubicin hycrochloride)
Indications
References
- ↑ "NCI Thesaurus".
- ↑ Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF; et al. (2010). "Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma". Blood. 115 (15): 3008–16. doi:10.1182/blood-2009-08-231613. PMC 2858478. PMID 20023215.
- ↑ Higashide Y, Hayashi T, Hirayama D, Wagatsuma K, Aoki Y, Maruyama Y; et al. (2015). "[A Case of Primary Mediastinal(Thymic)B-Cell Lymphoma Successfully Treated with the DA-EPOCH-RR egimen]". Gan To Kagaku Ryoho. 42 (1): 119–22. PMID 25596693.